TY - Jour A2 - Anglani，Franca Au - Alfano，Gaetano Au - Delrio，Alice Au - Fontana，Francesco Au - Mori，Giacomo Au - Cazzato，Silvia Au - Ferrari，Annachiara Au - Perrone，Rossella Au - Giovanella，Silvia Au -Ligabue，Giulia Au - Magistroni，Riccardo Au - Cappelli，Gianni Py - 2021 Da - 2021/05/13 Ti - 临床演示文稿，肾组织病理学发现，肾病患者的结果SP - 8859340 VL - 2021 AB -单克隆血换与急性和慢性肾损伤有关。分泌的单克隆（M） - 蛋白的肾毒性与其生物学性质和血液浓度有关。对肾病患者的流行病学，临床表现和单克隆术语结果众所周知。我们回顾了所有患者的人口统计，临床表现和肾组织学病变的数据（ N = 1334) who underwent kidney biopsy between January 2000 and March 2017. Monoclonal gammopathy was detected in 174 (13%) patients with a mean age of 66.4 ± 13.1 years. The spectrum of monoclonal gammopathies comprised monoclonal gammopathy of undetermined significate (MGUS) (52.8%), multiple myeloma (MM) (25.2%), primary amyloidosis (AL) (9.1%), smoldering MM (SMM) (4%), non-Hodgkin lymphoma (NHL) (6.8%), and Hodgkin lymphoma (HL) (1.7%). Monoclonal gammopathy of renal significance (MGRS) accounted for 6.5% in patients with MGUS and 14.2% in patients with SMM. Evaluation of kidney biopsy revealed that M-protein was directly involved in causing kidney injury in MM (93.1%). MM was the only gammopathy significantly associated with an increased risk of kidney injury (odds ratio [OR] = 47.5, CI 95%, 13.7–164.9; P. ≤. 0.001 ）。虽然终末期肾病或透析的进展没有显着差异 P. = 0.776 ，单克隆血曲调有关与不同的死亡风险有关 P. = 0.047 在随访结束时。总之，单克隆γ疗法是在肾活检的患者中常常发现（13％）。M-蛋白被过急剂（56.8％）和恶性（43.2％）淋巴抑制性克隆分泌。肾脏活检在鉴定MGU患者（6.5％）和SMM（14.2％）中具有关键作用。在单克隆术语中，只有MM与活检证明的肾损伤显着相关。单克隆术语中，末期肾病或透析率相似，而NHL，MM和SMM显示出更高的死亡率。SN - 2090-214X UR - https://doi.org/10.1155/2021/8859340 do - 10.1155 / 2021/8859340 jf - 国际肾脏学杂志 - Hindawi Kw - Er -